Global Antivenene 麻豆原创 Research Report 2023

Publication ID:

PB511236049

Publication Date:

November 3, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Antivenene, also known as antivenom, is a medical treatment used to counteract the effects of venom from poisonous animals, such as snakes, spiders, scorpions, and insects. It is produced by immunizing animals, such as horses or sheep, with controlled amounts of venom. The antibodies generated in these animals' blood are then collected and purified to create antivenene. When administered to humans bitten or stung by venomous creatures, antivenene neutralizes the toxins and prevents severe or life-threatening reactions.
The global Antivenene market is projected to reach US$ 1299.8 million in 2029, increasing from US$ 959 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2029.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Antivenene market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Segment by Type
Polyvalent Antivenene
Monovalent Antivenene
Segment by Application
Non-profit Institutions
Hospitals and Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Antivenene report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers鈥� Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers鈥� Outline
Chapter 7: Industry Chain, 麻豆原创 Channel and Customer Analysis
Chapter 8: 麻豆原创 Opportunities and Challenges
Chapter 9: 麻豆原创 Conclusions
Chapter 10: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Antivenene 麻豆原创 Overview
1.1 Product Overview and Scope of Antivenene
1.2 Antivenene Segment by Type
1.2.1 Global Antivenene 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Polyvalent Antivenene
1.2.3 Monovalent Antivenene
1.3 Antivenene Segment by Application
1.3.1 Global Antivenene 麻豆原创 Value by Application: (2023-2029)
1.3.2 Non-profit Institutions
1.3.3 Hospitals and Clinic
1.4 Global Antivenene 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Antivenene Revenue 2018-2029
1.4.2 Global Antivenene Sales 2018-2029
1.4.3 Global Antivenene 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Antivenene 麻豆原创 Competition by Manufacturers
2.1 Global Antivenene Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Antivenene Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Antivenene Average Price by Manufacturers (2018-2023)
2.4 Global Antivenene Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Antivenene, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antivenene, Product Type & Application
2.7 Antivenene 麻豆原创 Competitive Situation and Trends
2.7.1 Antivenene 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antivenene Players 麻豆原创 Share by Revenue
2.7.3 Global Antivenene 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antivenene Retrospective 麻豆原创 Scenario by Region
3.1 Global Antivenene 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Antivenene Global Antivenene Sales by Region: 2018-2029
3.2.1 Global Antivenene Sales by Region: 2018-2023
3.2.2 Global Antivenene Sales by Region: 2024-2029
3.3 Global Antivenene Global Antivenene Revenue by Region: 2018-2029
3.3.1 Global Antivenene Revenue by Region: 2018-2023
3.3.2 Global Antivenene Revenue by Region: 2024-2029
3.4 North America Antivenene 麻豆原创 Facts & Figures by Country
3.4.1 North America Antivenene 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Antivenene Sales by Country (2018-2029)
3.4.3 North America Antivenene Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antivenene 麻豆原创 Facts & Figures by Country
3.5.1 Europe Antivenene 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Antivenene Sales by Country (2018-2029)
3.5.3 Europe Antivenene Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antivenene 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Antivenene 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Antivenene Sales by Country (2018-2029)
3.6.3 Asia Pacific Antivenene Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antivenene 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Antivenene 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Antivenene Sales by Country (2018-2029)
3.7.3 Latin America Antivenene Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antivenene 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Antivenene 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Antivenene Sales by Country (2018-2029)
3.8.3 Middle East and Africa Antivenene Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antivenene Sales by Type (2018-2029)
4.1.1 Global Antivenene Sales by Type (2018-2023)
4.1.2 Global Antivenene Sales by Type (2024-2029)
4.1.3 Global Antivenene Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Antivenene Revenue by Type (2018-2029)
4.2.1 Global Antivenene Revenue by Type (2018-2023)
4.2.2 Global Antivenene Revenue by Type (2024-2029)
4.2.3 Global Antivenene Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Antivenene Price by Type (2018-2029)
5 Segment by Application
5.1 Global Antivenene Sales by Application (2018-2029)
5.1.1 Global Antivenene Sales by Application (2018-2023)
5.1.2 Global Antivenene Sales by Application (2024-2029)
5.1.3 Global Antivenene Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Antivenene Revenue by Application (2018-2029)
5.2.1 Global Antivenene Revenue by Application (2018-2023)
5.2.2 Global Antivenene Revenue by Application (2024-2029)
5.2.3 Global Antivenene Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Antivenene Price by Application (2018-2029)
6 Key Companies Profiled
6.1 CSL
6.1.1 CSL Corporation Information
6.1.2 CSL Description and Business Overview
6.1.3 CSL Antivenene Sales, Revenue and Gross Margin (2018-2023)
6.1.4 CSL Antivenene Product Portfolio
6.1.5 CSL Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Antivenene Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Merck Antivenene Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 BTG
6.3.1 BTG Corporation Information
6.3.2 BTG Description and Business Overview
6.3.3 BTG Antivenene Sales, Revenue and Gross Margin (2018-2023)
6.3.4 BTG Antivenene Product Portfolio
6.3.5 BTG Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Antivenene Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Antivenene Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Haffkine Bio-Pharmaceutical
6.5.1 Haffkine Bio-Pharmaceutical Corporation Information
6.5.2 Haffkine Bio-Pharmaceutical Description and Business Overview
6.5.3 Haffkine Bio-Pharmaceutical Antivenene Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Haffkine Bio-Pharmaceutical Antivenene Product Portfolio
6.5.5 Haffkine Bio-Pharmaceutical Recent Developments/Updates
6.6 Rare Disease Therapeutics
6.6.1 Rare Disease Therapeutics Corporation Information
6.6.2 Rare Disease Therapeutics Description and Business Overview
6.6.3 Rare Disease Therapeutics Antivenene Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Rare Disease Therapeutics Antivenene Product Portfolio
6.6.5 Rare Disease Therapeutics Recent Developments/Updates
6.7 Flynn Pharma
6.6.1 Flynn Pharma Corporation Information
6.6.2 Flynn Pharma Description and Business Overview
6.6.3 Flynn Pharma Antivenene Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Flynn Pharma Antivenene Product Portfolio
6.7.5 Flynn Pharma Recent Developments/Updates
6.8 Vins Bioproducts
6.8.1 Vins Bioproducts Corporation Information
6.8.2 Vins Bioproducts Description and Business Overview
6.8.3 Vins Bioproducts Antivenene Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Vins Bioproducts Antivenene Product Portfolio
6.8.5 Vins Bioproducts Recent Developments/Updates
6.9 Bharat Serums and Vaccines
6.9.1 Bharat Serums and Vaccines Corporation Information
6.9.2 Bharat Serums and Vaccines Description and Business Overview
6.9.3 Bharat Serums and Vaccines Antivenene Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Bharat Serums and Vaccines Antivenene Product Portfolio
6.9.5 Bharat Serums and Vaccines Recent Developments/Updates
6.10 Serum Biotech
6.10.1 Serum Biotech Corporation Information
6.10.2 Serum Biotech Description and Business Overview
6.10.3 Serum Biotech Antivenene Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Serum Biotech Antivenene Product Portfolio
6.10.5 Serum Biotech Recent Developments/Updates
6.11 MicroPharm
6.11.1 MicroPharm Corporation Information
6.11.2 MicroPharm Antivenene Description and Business Overview
6.11.3 MicroPharm Antivenene Sales, Revenue and Gross Margin (2018-2023)
6.11.4 MicroPharm Antivenene Product Portfolio
6.11.5 MicroPharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antivenene Industry Chain Analysis
7.2 Antivenene Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antivenene Production Mode & Process
7.4 Antivenene Sales and 麻豆原创ing
7.4.1 Antivenene Sales Channels
7.4.2 Antivenene Distributors
7.5 Antivenene Customers
8 Antivenene 麻豆原创 Dynamics
8.1 Antivenene Industry Trends
8.2 Antivenene 麻豆原创 Drivers
8.3 Antivenene 麻豆原创 Challenges
8.4 Antivenene 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.